Cidara Thera (CDTX) Stock Price, Quote & News

Latest News on CDTX

Apr 1, 2025, 4:56 PM EDT - 2 days ago

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Apr 1, 2025, 4:05 PM EDT - 2 days ago

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 8:00 AM EDT - 16 days ago

Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

Mar 18, 2025, 8:00 AM EDT - 17 days ago

Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

Mar 17, 2025, 6:00 AM EDT - 18 days ago

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology

Mar 6, 2025, 4:35 PM EST - 4 weeks ago

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 4:15 PM EST - 6 weeks ago

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

Feb 11, 2025, 8:22 AM EST - 7 weeks ago

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Jan 30, 2025, 4:05 PM EST - 2 months ago

Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Nov 21, 2024, 3:12 PM EST - 4 months ago

Cidara: Potential To Change Flu Prophylaxis Landscape With CD388

Nov 21, 2024, 8:30 AM EST - 4 months ago

Cidara Therapeutics Announces $105 Million Private Placement

Nov 19, 2024, 8:00 AM EST - 4 months ago

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

Nov 7, 2024, 4:15 PM EST - 5 months ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 8:00 AM EDT - 5 months ago

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

Sep 25, 2024, 8:00 AM EDT - 6 months ago

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

Sep 23, 2024, 8:00 AM EDT - 6 months ago

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

Sep 19, 2024, 8:00 AM EDT - 7 months ago

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

Sep 12, 2024, 4:05 PM EDT - 7 months ago

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

Sep 5, 2024, 8:00 AM EDT - 7 months ago

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 5:12 PM EDT - 8 months ago

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

Aug 13, 2024, 4:29 PM EDT - 8 months ago

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 3, 2024, 1:05 PM EDT - 9 months ago

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2024, 8:00 AM EDT - 11 months ago

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

May 15, 2024, 4:20 PM EDT - 11 months ago

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:01 PM EDT - 11 months ago

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Apr 26, 2024, 6:01 PM EDT - 1 year ago

Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform

Apr 26, 2024, 8:00 AM EDT - 1 year ago

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

Apr 24, 2024, 7:19 PM EDT - 1 year ago

Cidara Therapeutics shares surge 30% after reacquiring flu treatment

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Apr 22, 2024, 5:10 PM EDT - 1 year ago

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Apr 22, 2024, 5:06 PM EDT - 1 year ago

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

Apr 22, 2024, 8:49 AM EDT - 1 year ago

Cidara Therapeutics Announces Reverse Stock Split

Apr 5, 2024, 3:00 PM EDT - 1 year ago

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

Feb 12, 2024, 8:00 AM EST - 1 year ago

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Jan 29, 2024, 4:30 PM EST - 1 year ago

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Dec 22, 2023, 7:30 AM EST - 1 year ago

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

Dec 7, 2023, 8:00 AM EST - 1 year ago

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Dec 6, 2023, 8:00 AM EST - 1 year ago

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Dec 5, 2023, 9:00 AM EST - 1 year ago

Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID

Nov 30, 2023, 8:00 AM EST - 1 year ago

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Nov 20, 2023, 8:00 AM EST - 1 year ago

Cidara Therapeutics Named as a San Diego Metro Area Top Workplace

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC's 38ᵗʰ Annual Meeting

Nov 2, 2023, 4:15 PM EDT - 1 year ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 13, 2023, 10:34 AM EDT - 1 year ago

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

Oct 13, 2023, 10:21 AM EDT - 1 year ago

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

Oct 11, 2023, 8:30 AM EDT - 1 year ago

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023

Sep 22, 2023, 7:48 PM EDT - 1 year ago

Market Cap	207.23M
Revenue (ttm)	1.28M
Net Income (ttm)	-169.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,267.97%
Debt to Equity Ratio	0.00

Volume	83,731
Avg Vol	121,572
Day's Range	N/A - N/A
Shares Out	10.95M
Stochastic %K	5%
Beta	0.89
Analysts	Strong Sell
Price Target	$38.00